Laura is the editorial director of The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®'s parent company, MJH Life Sciences, since 2011. She has an MA in business and economic reporting from New York University.
Among patients with rheumatic diseases, medication nonadherence remains a significant problem because of a lack of standardization and guidance on terminology, measurement, and outcome selection, according to an abstract presented at the European Congress of Rheumatology of the European League Against Rheumatism.
Among patients with rheumatic diseases, medication nonadherence remains a significant problem because of a lack of standardization and guidance on terminology, measurement, and outcome selection, according to an abstract presented at the European Congress of Rheumatology of the European League Against Rheumatism.1
The authors interviewed 13 researchers to understand their perspectives and experiences on adherence intervention research and outcomes in rheumatology. The researchers interviewed had been an investigator on an adherence study in the past 10 years. They represented 7 countries—Australia, Belgium, Canada, the Netherlands, Thailand, the United Kingdom, and the United States—and a majority worked in academic (75%).
The researchers identified 3 themes:
“Our findings form the basis for recommendations for improving the design, conduct, and evaluation of adherence intervention studies in rheumatology, particularly for developing a core domain set of outcomes to improve consistency and facilitate comparisons,” the authors concluded.
In a separate abstract, researchers from Spain sought to understand the patient’s perspective regarding nonadherence.2 According to the authors, the nonadherence rate in patients with RA ranges between 20% and 50%, and poor adherence has a negative impact on outcomes.
The authors included 144 patients with rheumatoid arthritis (RA) in a cross-sectional study and used the Compliance Questionnaire Rheumatology to assess treatment adherence and the Brief Illness Perception Questionnaire and the Beliefs About Medicine Questionnaire to evaluate illness and medication beliefs.
The belief that the drugs can cause potential damage was associated with poor compliance while the belief that the medication was necessary was associated with good compliance. Patients who had a feeling of treatment control were more likely to be adherent, as were patients with a greater emotional response.
“Illness and medication beliefs could influence compliance to treatment in patients with RA,” the authors concluded.
1. Kelly A, Salmasi S, Bartlett SJ, et al. Researchers’ perspectives on adherence intervention research and outcomes in rheumatology: An international qualitative study. Presented at: EULAR 2020; June 3-6, 2020; Abstract THU0565. https://ard.bmj.com/content/79/Suppl_1/524.2
2. Ahijón M, Carreira P, De La Cruz C, Veiga R, Gutierrez C. Implicated factors in therapeutic adherence of patients with rheumatoid arthritis: the patient’s perspective. Presented at: EULAR 2020; June 3-6, 2020; Abstract SAT0616-HPR. https://ard.bmj.com/content/79/Suppl_1/1268.1